Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan flat-sum changes may boost generic uptake further

This article was originally published in Scrip

Executive Summary

Japan's central social insurance medical council (Chuikyo) is debating a possible change to the diagnosis procedure combination (DPC) reimbursement system to encourage the use of generic drugs. But at a recent council hearing, no consensus was reached on a ministry of health, labour and welfare proposal to better reward generic use under the DPC evaluation system. The DPC programme involves flat-sum reimbursement for all acute inpatient care costs, including drugs, and is being implemented at an increasing number of hospitals in Japan. It is itself expected to drive generic uptake, as hospitals look to contain costs within the fixed figure (Scrip Online, October 7th, 2008).

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC031695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel